![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
Weill Medical College of Cornell University National Cancer Institute (NCI) |
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00119249 |
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
PURPOSE: This phase II trial is studying how well sorafenib works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery.
Condition | Intervention | Phase |
Melanoma (Skin) |
Drug: sorafenib tosylate |
Phase II |
MedlinePlus related topics: | Cancer Melanoma |
ChemIDplus related topics: | Sorafenib Sorafenib tosylate |
Study Type: | Interventional |
Study Design: | Treatment, Open Label |
Official Title: | A Phase II Study of BAY 43-9006 (NSC 724772) in Unresectable Stage III and Stage IV Melanoma |
Estimated Enrollment: | 74 |
Study Start Date: | June 2005 |
Estimated Primary Completion Date: | May 2007 (Final data collection date for primary outcome measure) |
OBJECTIVES:
Primary
Secondary
OUTLINE: This is a multicenter study. Patients are stratified according to presence of BRAF gene mutation in tumor sample (yes vs no).
Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed annually.
PROJECTED ACCRUAL: A total of 26-74 patients (13-37 per stratum) will be accrued for this study within 5.2-18.5 months.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed unresectable melanoma
Brain metastases allowed provided the following criteria are met:
PATIENT CHARACTERISTICS:
Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Cardiovascular
Other
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Other
United States, New York | |||||
New York Weill Cornell Cancer Center at Cornell University | |||||
New York, New York, United States, 10021 | |||||
NYU Cancer Institute at New York University Medical Center | |||||
New York, New York, United States, 10016 | |||||
Australia, New South Wales | |||||
Sydney Cancer Centre at Royal Prince Alfred Hospital | |||||
Sydney, New South Wales, Australia, 2050 |
Weill Medical College of Cornell University |
National Cancer Institute (NCI) |
Study Chair: | Anna Pavlick, MD | New York University School of Medicine |
Clinical trial summary from the National Cancer Institute's PDQ® database 
![]()   |
Min C, Liebes L, Brooks P, et al.: Phase II trial of BAY 43-9006 (sorafenib-BAY) in metastatic
melanoma (MM) including detection of BRAF mutations with
mutant specific-PCR (MS-PCR) and altered proliferation pathways. [Abstract] American Association for Cancer Research: Molecular Targets and Cancer Therapeutics, October 22-26, 2007, San Francisco, CA A-B254, 2007.
  |
Study ID Numbers: | CDR0000434613, NYWCCC-NYU-0438, NCI-6617 |
First Received: | July 12, 2005 |
Last Updated: | July 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00119249 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|
![]() |